An Open Label, Multi-Center Phase 1b/2a Trial Investigating Different Doses of Sym004 in Combination With FOLFIRI in Patients With Metastatic Colorectal Cancer Progressing After First Line Therapy
Phase of Trial: Phase I/II
Latest Information Update: 13 Jul 2018
At a glance
- Drugs Futuximab/modotuximab (Primary) ; Fluorouracil; Folinic acid; Irinotecan
- Indications Colorectal cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Symphogen
- 06 Jun 2018 Status changed from active, no longer recruiting to discontinued.
- 26 Dec 2017 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.
- 23 Jun 2017 Planned End Date changed from 1 Jun 2018 to 1 Dec 2017.